Windtree Therapeutics Announces Board and Compensation Changes
Ticker: WINTW · Form: 8-K · Filed: Jan 13, 2025 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
Windtree Therapeutics shakes up its board and executive pay structure.
AI Summary
Windtree Therapeutics, Inc. announced on January 8, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain directors and the election of new ones, alongside adjustments to officer compensation.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal restructuring or strategic shifts that may carry inherent risks.
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific reasons were given for the departure of directors?
The filing indicates departures under Item 5.02(b) but does not specify the reasons for each departure.
Who are the newly elected directors?
The filing mentions the election of directors under Item 5.02(c) but does not list their names in the provided text.
What are the key changes in executive compensation arrangements?
The filing notes changes to compensatory arrangements under Item 5.02(e) but does not detail the specific adjustments.
When was the earliest event reported in this 8-K filing?
The earliest event reported is January 8, 2025.
What is Windtree Therapeutics' Standard Industrial Classification (SIC) code?
Windtree Therapeutics' SIC code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 924 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2025-01-13 08:09:00
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma
Filing Documents
- wint20250112_8k.htm (8-K) — 28KB
- ex_764827.htm (EX-99.1) — 11KB
- 0001437749-25-000930.txt ( ) — 178KB
- wint-20250108.xsd (EX-101.SCH) — 3KB
- wint-20250108_def.xml (EX-101.DEF) — 12KB
- wint-20250108_lab.xml (EX-101.LAB) — 15KB
- wint-20250108_pre.xml (EX-101.PRE) — 12KB
- wint20250112_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On December 4, 2024, the Company received a notification letter from the Nasdaq Listing Qualification Department stating that the Company was no longer in compliance with Nasdaq's independent director and auditor committee requirements as set forth in Listing Rule 5605. The Company expects that Ms. Kelly's appointment as an independent director and a member of the Audit Committee will resolve the Nasdaq deficiency.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Press Release of Windtree Therapeutics, Inc., dated January 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Windtree Therapeutics, Inc. By: /s/ Jed Latkin Name: Jed Latkin Title: President and Chief Executive Officer Date: January 13, 2025